116
Participants
Start Date
November 21, 2018
Primary Completion Date
October 16, 2020
Study Completion Date
October 16, 2020
OLP-1002 (Test): Part A, Single Ascending Dose
Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 µg, 3 µg, 6 µg, 12 µg, 20 µg, 40 μg, 80 μg, 160 μg
OLP-1002 (Test): Part B, Multiple Ascending Dose
Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg
Placebo: Placebo Part A, Single Ascending Dose
Subcutaneous Injection: Placebo
Placebo: Placebo Part B, Multiple Ascending Dose
Subcutaneous Injection: Placebo x 5
Leeds CRU, Leeds
Lead Sponsor
OliPass Corporation
INDUSTRY